Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03933631 · ClinicalTrials.gov registry record · Phase 3
Pilocarpine Use After Kahook Goniotomy
A Phase 3 study of Glaucoma, sponsored by Montefiore Medical Center.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 142
- Enrollment target
- 2
- Study locations
NCT03933631: Recruiting Phase 3 study of Glaucoma, sponsored by Montefiore Medical Center.
NCT03933631 is a Phase 3 study of Glaucoma that is actively recruiting participants, run by Montefiore Medical Center. The registered enrollment target is 142 participants, below the 909-participant average among 92 other Glaucoma trials with a reported enrollment target (84% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03933631, a Phase 3 study of Glaucoma, is actively recruiting participants, sponsored by Montefiore Medical Center.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 142 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this study is to determine whether using pilocarpine provides added benefit to the success of combined cataract + Kahook Dual Blade (KDB) surgery.
Primary Outcome
The percentage of patients who had a reduction in IOP of 20% or more from baseline will be summarized by study arm using descriptive statistics.
Conditions Studied
Interventions
- DRUG Prednisolone
- DRUG Pilocarpine
- DRUG Ofloxacin
Study Locations (2)
New York
- Montefiore Wakefield Campus - The Bronx
- Montefiore Medical Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2028-12 |
| Phase | Phase 3 |
What NCT03933631 shows while recruiting
NCT03933631 is an interventional study that assigns participants to a tested intervention. The registered 142 participants enrollment target is mid-sized for trials with a published cap, below the 909-participant average among 92 other Glaucoma trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Glaucoma appearing as the primary indexed condition, and to 3 interventions - of which Prednisolone is the first listed.
NCT03933631 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03933631 about?
NCT03933631 is a clinical study titled "Pilocarpine Use After Kahook Goniotomy". The goal of this study is to determine whether using pilocarpine provides added benefit to the success of combined cataract + Kahook Dual Blade (KDB) surgery.
What is the current status of trial NCT03933631?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 142 participants. The study started on 2019-05-01. Estimated completion is 2028-12.
What conditions does trial NCT03933631 study?
This clinical trial studies the following conditions: Glaucoma.
What interventions are being tested in trial NCT03933631?
The interventions under investigation include: Prednisolone (DRUG), Pilocarpine (DRUG), Ofloxacin (DRUG).
Who is sponsoring clinical trial NCT03933631?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03933631 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03933631's enrollment target sits among peer trials
142 36th of 92 higher than 57 of 92 other Glaucoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
RECRUITING · Phase 3
-
Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients
COMPLETED · Phase 3
-
Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension
COMPLETED · Phase 3
-
Functional and Structural Imaging for Glaucoma
RECRUITING
-
Topical Insulin for Glaucoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04938349 · 142 participants · NA
Dual Task Perturbation Training for OAwMCI
- NCT06117254 · 142 participants · NA
Hearing Aids for Veterans With Functional Hearing Difficulties
- NCT06463665 · 142 participants · Phase 2
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
- NCT06524830 · 142 participants · Phase 2
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI